🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. SAR231893 (REGN668)

    Regeneron UK Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  2. SAR231893 (REGN668) DP1

    Regeneron UK Limited

    Healthy

    phase 1 mab completed

    1 trial

  3. SC-DARIC33

    Regeneron UK Limited

    Acute Myeloid Leukemia

    phase 1 mab active

    1 trial

  4. SECRET-HF: Treatment of Non-ischemic Dilated Cardiomyopathies by Intravenous Infusions of the Extracellular Vesicle-Enriched Secretome of Cardiovascular Progenitor Cells

    Pari Pharma GmbH

    Non-ischemic Dilated Cardiomyopathies

    phase 1 other active

    1 trial

  5. SKY0402

    Pacira Ireland Limited

    Postoperative Pain Management

    phase 1 small molecule completed

    1 trial

  6. Safety and Early Signs of Efficacy of IL12-L19L19

    Philogen S.p.A.

    Advanced or metastatic carcinomas after previous immune checkpoint blockade therapy

    phase 1 other active

    1 trial

  7. Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus placebo in trial participants with moderate to severe plaque psoriasis (double-blind, randomised, placebo-controlled, parallel-group design)

    Boehringer Ingelheim

    Plaque psoriasis

    phase 1 other active

    1 trial

  8. Sargramostim

    Ultragenyx UK Limited

    Autoimmune Pulmonary Alveolar Proteinosis

    phase 1 small molecule completed

    1 trial

  9. Segesterone Acetate and Ethinyl Estradiol

    TherapeuticsMD

    Contraception

    phase 1 small molecule completed

    1 trial

  10. Segesterone Acetate and Ethinyl Estradiol

    TherapeuticsMD

    Women

    phase 1 small molecule completed

    1 trial

  11. Shigella sonnei 53G

    United Therapeutics Europe Ltd

    Shigellosis

    phase 1 mab active

    2 trials

  12. Shigella sonnei 53G

    United Therapeutics Europe Ltd

    Healthy

    phase 1 mab completed

    1 trial

  13. Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults with Severe Immunoglobulin E (IgE)-Mediated Food Allergy

    Lacuna Pharma Pty Ltd

    Severe IgE-mediated food allergy

    phase 1 other active

    1 trial

  14. Sialic Acid Extended Release (SA-ER) Tablets

    Ultragenyx UK Limited

    Hereditary Inclusion Body Myopathy (HIBM)

    phase 1 small molecule completed

    1 trial

  15. Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 1 small molecule active

    1 trial

  16. Single microdose trial - CXCR4 PET tracer - Pharmacokinetics and pharmacodynamics of [68Ga]Ga-R54, a CXCR4-targeted radiopharmaceutical in patients with advanced solid tumors.

    Fondazione Telethon ETS

    Advanced solid neoplasm (breast, lung, colon, ovary, pancreas) characterized by positive CXCR4 expression by immunohistochemistry

    phase 1 other active

    1 trial

  17. Single-Dose Study in Healthy Participants to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg Under Fasting Conditions, and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg Under Fasting versus Fed Conditions.

    The George Institute

    No medical condition.

    phase 1 other active

    1 trial

  18. Spesolimab

    Boehringer Ingelheim

    Psoriasis

    phase 1 small molecule completed

    1 trial

  19. Spinraza 12 mg solution for injection

    Biogen

    Spinal Muscular Atrophy

    phase 1 small molecule active

    1 trial

  20. Sporozoite Challenge Model for Plasmodium vivax in Humans

    BRIGHT MINDS BIOSCIENCES INC.

    Malaria, Vivax

    phase 1 mab completed

    1 trial

  21. Stem Cell

    EuroGen Pharmaceuticals Ltd

    Neurological; Disorder, Nervous System

    phase 1 mab terminated

    1 trial

  22. Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast Cancer

    Eli Lilly Co.

    Lung Cancer or Breast Cancer

    phase 1 other active

    1 trial

  23. Study of EGF816 in combination with selected targeted agents in EGFR-mutant NSCLC.

    Novartis Pharmaceuticals

    Patients with EGFR-mutant Non Small Cell Lung Cancer

    phase 1 other active

    1 trial

  24. Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

    Merck Sharp and Dohme

    Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD-1-exposed Advanced/Met HNSCC, Advanced/Met HNSCC, Advanced/Met NSCLC, Advance/Met RCC, Advanced/Met Gastric or GEJ adenocarcinoma, Ovarian Cancer. TNBC, Advanced Mesothelioma, Advanced Solid tumors(coformulation)

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources